Suppr超能文献

应用体内微透析技术描述糖尿病慢性创面感染患者替加环素的组织渗透和药代动力学。

Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

机构信息

Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.

出版信息

Antimicrob Agents Chemother. 2010 Dec;54(12):5209-13. doi: 10.1128/AAC.01051-10. Epub 2010 Oct 4.

Abstract

Tissue penetration of systemic antibiotics is an important consideration for positive outcomes in diabetic patients. Herein we describe the exposure profile and penetration of tigecycline in the interstitial fluid of wound margins versus that of uninfected thigh tissue in 8 adult diabetic patients intravenously (IV) administered 100 mg and then 50 mg of tigecycline twice daily for 3 to 5 doses. Prior to administration of the first dose, 2 microdialysis catheters were inserted into the subcutaneous tissue, the first within 10 cm of the wound margin and the second in the thigh of the same extremity. Samples for determination of plasma and tissue concentrations were simultaneously collected over 12 h under steady-state conditions. Tissue concentrations were corrected for percent in vivo recovery by the retrodialysis technique. Plasma samples were also collected for determination of protein binding at 1, 6, and 12 h postdose for each patient. Protein binding data were corrected using a fitted polynomial equation. The mean patient weight was 95.1 kg (range, 63.6 to 149.2 kg), the mean patient age was 63.5 ± 9.4 years, and 75% of the patients were males. The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively. Protein binding was nonlinear, with the percentage of free drug increasing with decreasing serum concentrations. Exposure values for thigh tissue and wound tissue were similar (P = 0.986). Mean steady-state tissue concentrations for the thigh and wound were similar at 0.12 ± 0.02 μg/ml, and clearance from the tissues appeared similar to that from plasma. Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964). Tigecycline penetrated equally well into wound and uninfected tissue of the same extremity.

摘要

全身用抗生素在糖尿病患者中的组织穿透性是获得良好治疗效果的一个重要考量因素。在此,我们描述了 8 例成年糖尿病患者静脉(IV)给予 100 mg 后再给予 50 mg 替加环素,每日 2 次,共 3-5 剂时,替加环素在伤口边缘的间质液与未感染的大腿组织中的暴露概况和穿透情况。在给予首剂前,将 2 个微透析导管插入皮下组织,第一个导管位于伤口边缘 10 cm 以内,第二个导管位于同一肢体的大腿内。在稳态条件下,通过同时收集 12 小时的组织和血浆样本,来测定组织和血浆浓度。通过逆行透析技术,对组织浓度进行了体内回收率的校正。还在每个患者给药后 1、6 和 12 小时时收集血浆样本,以测定蛋白结合率。使用拟合多项式方程校正蛋白结合数据。患者平均体重为 95.1 kg(范围,63.6-149.2 kg),平均年龄为 63.5 ± 9.4 岁,75%的患者为男性。从 0 到 24 小时的血浆、大腿和伤口游离区浓度-时间曲线下面积(fAUC(0-24))的平均值分别为 2.65 ± 0.33、2.52 ± 1.15 和 2.60 ± 1.02 μg·h/ml。蛋白结合呈非线性,游离药物的百分比随血清浓度的降低而增加。大腿组织和伤口组织的暴露值相似(P = 0.986)。大腿和伤口的组织达到稳态浓度相似,分别为 0.12 ± 0.02 μg/ml,且药物从组织中的清除率与从血浆中的清除率相似。组织穿透率(组织 fAUC/血浆 fAUC)在大腿和伤口处均为 99%(P = 0.964)。替加环素均匀地渗透到同一肢体的伤口和未感染组织中。

相似文献

1
3
Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis.
Antimicrob Agents Chemother. 2011 Sep;55(9):4170-5. doi: 10.1128/AAC.00445-11. Epub 2011 Jun 27.
4
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Antimicrob Agents Chemother. 2009 Mar;53(3):1165-9. doi: 10.1128/AAC.00647-08. Epub 2008 Dec 29.
5
Tissue pharmacokinetics of cefazolin in patients with lower limb infections.
Antimicrob Agents Chemother. 2013 Nov;57(11):5679-83. doi: 10.1128/AAC.01348-13. Epub 2013 Sep 16.
6
In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers.
Antimicrob Agents Chemother. 2008 Nov;52(11):3941-6. doi: 10.1128/AAC.00589-08. Epub 2008 Sep 8.
8
Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
Antimicrob Agents Chemother. 2009 Dec;53(12):5060-3. doi: 10.1128/AAC.00985-09. Epub 2009 Sep 8.
9
Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00345-17. Print 2017 Aug.
10
In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
Antimicrob Agents Chemother. 2009 Jul;53(7):2756-61. doi: 10.1128/AAC.01678-08. Epub 2009 Apr 13.

引用本文的文献

3
Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults.
Clin Pharmacokinet. 2024 Jul;63(7):965-980. doi: 10.1007/s40262-024-01394-z. Epub 2024 Jul 2.
4
Microdialysis as a tool for antibiotic assessment in patients with diabetic foot: a review.
Front Endocrinol (Lausanne). 2023 Apr 17;14:1141086. doi: 10.3389/fendo.2023.1141086. eCollection 2023.
5
Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.
Antibiotics (Basel). 2022 Sep 3;11(9):1193. doi: 10.3390/antibiotics11091193.
6
Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis.
Eur J Drug Metab Pharmacokinet. 2022 Sep;47(5):749-755. doi: 10.1007/s13318-022-00789-2. Epub 2022 Aug 9.
7
An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.
Front Pharmacol. 2022 Jun 28;13:900551. doi: 10.3389/fphar.2022.900551. eCollection 2022.
8
Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
Eur J Clin Pharmacol. 2021 Feb;77(2):197-205. doi: 10.1007/s00228-020-02998-7. Epub 2020 Sep 25.
9
Nonlinear Protein Binding: Not What You Think.
J Pharm Sci. 2018 Jul;107(7):1754-1760. doi: 10.1016/j.xphs.2018.03.023. Epub 2018 Apr 4.

本文引用的文献

1
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Antimicrob Agents Chemother. 2009 Mar;53(3):1165-9. doi: 10.1128/AAC.00647-08. Epub 2008 Dec 29.
4
Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials.
Diabetes Res Clin Pract. 2008 Jun;80(3):344-51. doi: 10.1016/j.diabres.2008.01.009. Epub 2008 Mar 4.
5
Clinical microdialysis in skin and soft tissues: an update.
J Clin Pharmacol. 2008 Mar;48(3):351-64. doi: 10.1177/0091270007312152.
6
In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.
Pathol Biol (Paris). 2007 Nov;55(8-9):398-406. doi: 10.1016/j.patbio.2007.07.003. Epub 2007 Oct 1.
7
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. doi: 10.1128/AAC.01084-06. Epub 2007 Mar 12.
8
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
J Antimicrob Chemother. 2006 Dec;58(6):1221-9. doi: 10.1093/jac/dkl403. Epub 2006 Sep 29.
9
Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers.
Clin Microbiol Infect. 2006 Feb;12(2):186-9. doi: 10.1111/j.1469-0691.2005.01279.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验